ArticleBMC medical genetics2015
Pharmacogenetics and the print media: what is the public told?
Article in BMC medical genetics, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Personalizing Personalized Medicine: The Confluence of Pharmacogenomics, a Person's Medication Experience and Ethics.Pharmacy (Basel, Switzerland) · 2023Review
- Transvaginal mesh in Australia: An analysis of news media reporting from 1996 to 2021.Health expectations : an international journal of public participation in health care and health policy · 2023Article
- Potential of UK and US newspapers for shaping patients' knowledge and perceptions about antidiabetic medicines: a content analysis.Journal of pharmaceutical policy and practice · 2022Article
- Nature versus nurture-on the origins of a specious argument.Exposome · 2022Article
- Determinants of stakeholders' intention to adopt pharmacogenomic.The pharmacogenomics journal · 2020Article
- Implementing and assessing a service to demonstrate public impact of faculty research in news and policy sources.Journal of the Medical Library Association : JMLA · 2019Article
- Media Coverage of the Benefits and Harms of Testing the Healthy: a protocol for a descriptive study.BMJ open · 2019Article
- Patient characteristics, experiences and perceived value of pharmacogenetic testing from a single testing laboratory.Pharmacogenomics · 2019Article
- Health Care Apps Reported in Newspapers: Content Analysis.JMIR mHealth and uHealth · 2018Article
- What does mainstream media say about enzyme replacement therapies?Paediatrics & child health · 2018Article
- Improving coverage of medical research in a changing media environment.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2017Article
- Integrating pharmacogenetic testing into primary care.Expert review of precision medicine and drug development · 2017Article
- Who tweets what about personalised medicine? Promises and concerns from Twitter discussions in Denmark.Digital healthArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPharmacogenetics is a rapidly growing field that aims to identify the genes that influence drug response. This science can be used as a powerful tool to tailor drug treatment to the genetic makeup of individuals. The present study explores the coverage of the topic of pharmacogenetics and its potential benefit in personalised medicine by the UK newsprint media.
methodsThe LexisNexis database was used to identify and retrieve full text articles from the 10 highest circulation national daily newspapers and their Sunday equivalents in the UK. Content analysis of newspaper articles which referenced pharmacogenetic testing was carried out. A second researcher coded a random sample (21%) of newspaper articles to establish the inter-rater reliability of coding.
resultsOf the 256 articles captured by the search terms, 96 articles (with pharmacogenetics as a major component) met the study inclusion criteria. The majority of articles over-stated the benefits of pharmacogenetic testing while paying less attention to the associated risks. Overall beneficial effects were mentioned 5.3 times more frequently than risks (p < 0.001). The most common illnesses for which pharmacogenetically based personalised medicine was discussed were cancer, cardiovascular disease and CNS diseases. Only 13% of newspaper articles that cited a specific scientific study mentioned this link in the article. There was a positive correlation between the size of the article and both the number of benefits and risks stated (P < 0.01).
conclusionMore comprehensive coverage of the area of personalised medicine within the print media is needed to inform public debate on the inclusion of pharmacogentic testing in routine practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.